Clinical trial · Observational
Role of LncRNA H19 in The Regulation of IGF-1R Expression
Role of LncRNA H19 in The Regulation of IGF-1R Expression: A Possible Association Between Type 2 Diabetes and Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) is a common cancer that poses a heavy economic burden on the healthcare system. In Egypt, it is the most common cause of mortality and morbidity-related cancer. Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia. Cancer and type II diabetes (T2DM), the world's two most prevalent diseases, share many overlapping risk factors and predisposing pathological conditions. The exact mechanisms linking those two diseases are yet to be fully understood. In this study, the investigators aim to assess the relationship between Long Non-Coding RNA (lncRNA) H19 and Insulin-Like Growth Factor 1 Receptor (IGF-1R) mRNA gene expressions in the blood samples of HCC \& T2DM patients to investigate the probability of the presence of a pathophysiological link between HCC and DM that may become a therapeutic target for both diseases. To the investigator's knowledge, there is currently no human research study investigating both H19 and IGF-1R in both DM and cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Type 2 Diabetes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- HCC patients
- description
- Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
- interventionNames
- Other: Blood sample collection
- label
- T2DM patients
- description
- Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
- interventionNames
- Other: Blood sample collection
- label
- HCC & T2DM patients
- description
- Measure lncRNA H19 and IGF-1R mRNA gene expression levels in the collected blood samples.
- interventionNames
- Other: Blood sample collection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
• HCC cases (group I): Inclusion criteria: \- Patients aged 40 years or older with a confirmed diagnosis of HCC through triphasic CT and/or dynamic MRI (European Association for the Study of the Liver, 2012). Exclusion criteria: * Patients who underwent previous cancer-directed treatment (radiation and/or chemotherapy). * Patients with any other systemic disease (Renal disease, other primary tumors). * T2DM cases (group II): Inclusion criteria: \- Clinically diagnosed T2DM patients aged 40 years or older frequenting Mansoura Specialized Medical Hospital. Exclusion criteria: * Patients with previous or current malignancies. * Patients with diabetic complications (Diabetic retinopathy, neuropathy, nephropathy). * Patients with other systemic diseases. * HCC \& T2DM cases (group III): Inclusion criteria: \- Patients aged 40 years or older with a confirmed diagnosis of HCC through triphasic CT and/or dynamic MRI and who are clinically diagnosed to have T2DM. Exclusion criteria: * Patients who underwent previous cancer-directed treatment (radiation and/or chemotherapy). * Patients with any other systemic disease. • Controls (group IV): * Apparently healthy, age, and gender-matched subjects. * No history of malignant disease, diabetes, or HCV.
References
Publications (21)
- BACKGROUNDChen B, Li J, Chi D, Sahnoune I, Calin S, Girnita L, Calin GA. Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer. Cells. 2019 Dec 14;8(12):1638. doi: 10.3390/cells8121638. PMID 31847392
- BACKGROUNDChitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008 Oct 15;14(20):6364-70. doi: 10.1158/1078-0432.CCR-07-4879. PMID 18927274
- BACKGROUNDDing J, Li C, Tang J, Yi C, Liu JY, Qiu M. Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus. Pathol Oncol Res. 2016 Oct;22(4):773-9. doi: 10.1007/s12253-016-0065-6. Epub 2016 May 2. PMID 27138191
- BACKGROUNDFabbri M, Girnita L, Varani G, Calin GA. Decrypting noncoding RNA interactions, structures, and functional networks. Genome Res. 2019 Sep;29(9):1377-1388. doi: 10.1101/gr.247239.118. Epub 2019 Aug 21. PMID 31434680
- BACKGROUNDFarzi-Molan A, Babashah S, Bakhshinejad B, Atashi A, Fakhr Taha M. Down-regulation of the non-coding RNA H19 and its derived miR-675 is concomitant with up-regulation of insulin-like growth factor receptor type 1 during neural-like differentiation of human bone marrow mesenchymal stem cells. Cell Biol Int. 2018 Aug;42(8):940-948. doi: 10.1002/cbin.10960. Epub 2018 Mar 30. PMID 29512257
- BACKGROUNDFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9. PMID 25220842
- BACKGROUNDForner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.